List of Excipients in Branded Drug COARTEM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	COARTEM	artemether and lumefantrine	0078-0568	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	COARTEM	artemether and lumefantrine	0078-0568	CROSCARMELLOSE SODIUM
Novartis Pharmaceuticals Corporation	COARTEM	artemether and lumefantrine	0078-0568	HYPROMELLOSES
Novartis Pharmaceuticals Corporation	COARTEM	artemether and lumefantrine	0078-0568	MAGNESIUM STEARATE
Novartis Pharmaceuticals Corporation	COARTEM	artemether and lumefantrine	0078-0568	POLYSORBATE 80

Coartem Excipient Strategy, Formulation Patents, Generic Competition, and Commercial Opportunities

Last updated: October 15, 2026

Coartem is the fixed-dose artemether/lumefantrine antimalarial marketed by Novartis. Its commercial value is concentrated in pediatric suitability, dispersible-tablet performance, tropical-climate stability, palatability, and procurement access rather than in active-ingredient exclusivity. The principal excipient opportunities are improved taste masking, faster dispersion, lower tablet mass, lactose-free or sugar-free positioning, improved humidity resistance, and manufacturing platforms that reduce cost in public-health markets.

What is Coartem and which formulations are commercially important?

Coartem contains artemether and lumefantrine at a 20 mg/120 mg strength per tablet. The product is supplied in conventional tablets and Coartem Dispersible, a pediatric formulation that is dispersed in water before administration. The product is used for acute uncomplicated malaria caused by Plasmodium falciparum and is administered in a six-dose regimen over three days (Novartis Pharmaceuticals Corporation, 2023).

Product	Active ingredients per unit	Primary users	Commercial formulation issue
Coartem tablet	Artemether 20 mg; lumefantrine 120 mg	Adults and children meeting weight thresholds	Swallowability, dose adherence, tropical stability
Coartem Dispersible	Artemether 20 mg; lumefantrine 120 mg	Young children and patients unable to swallow tablets	Taste, rapid dispersion, sedimentation, dose recovery
Generic artemether/lumefantrine tablets	Usually 20 mg/120 mg	Public and private markets	Cost, bioequivalence, supply reliability
Pediatric dispersible generics	Usually 20 mg/120 mg	Children under standard tablet age	Palatability, excipient safety, manufacturing scale

The dispersible product is commercially significant because malaria burden is concentrated in regions where pediatric treatment, water access, temperature, humidity, and procurement price affect demand.

What excipients are used in Coartem tablets?

The U.S. prescribing information identifies excipients in Coartem tablets that support compression, disintegration, flow, lubrication, coating, and wetting. The tablet formulation includes lactose monohydrate, maize starch, croscarmellose sodium, hypromellose, magnesium stearate, colloidal silicon dioxide, polysorbate 80, and talc (Novartis Pharmaceuticals Corporation, 2023).

Excipient	Likely functional role	Strategic relevance
Lactose monohydrate	Diluent and compression aid	Supports low-cost tableting but creates lactose and formulation-positioning constraints
Maize starch	Binder and disintegrant	Widely available and economical; performance can vary by grade and moisture
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup and dissolution
Hypromellose	Binder and film former	Controls mechanical strength and coating performance
Magnesium stearate	Lubricant	Can affect wetting and dissolution if over-lubrication occurs
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and may reduce manufacturing variability
Polysorbate 80	Wetting or solubilization aid	Relevant because lumefantrine has poor aqueous solubility
Talc	Anti-adherent or coating aid	Supports processing and coating performance

The central formulation challenge is lumefantrine. It is highly lipophilic and poorly water-soluble, while artemether also presents formulation and stability challenges. Excipients must support consistent dissolution without compromising tablet robustness, taste, or tropical storage performance.

What excipients are used in Coartem Dispersible?

Coartem Dispersible uses a pediatric excipient strategy centered on rapid dispersion and improved acceptability. Product information identifies excipients including lactose monohydrate, maize starch, crospovidone, hypromellose, poloxamer 188, saccharin sodium, sodium stearyl fumarate, colloidal anhydrous silica, flavoring agents, and colorants. Exact composition can vary by market and manufacturing site, so the relevant national label controls for regulatory and competitive analysis (Novartis Pharmaceuticals Corporation, 2023; European Medicines Agency, 2009).

Formulation objective	Excipient approach	Commercial implication
Rapid dispersion	Crospovidone and starch	Reduces administration time and residue
Taste masking	Sweetener and flavor system	Can improve pediatric adherence
Wetting of hydrophobic drug particles	Poloxamer 188 and surfactant strategy	Supports dispersion and dissolution
Powder flow	Colloidal silica	Improves high-volume manufacturing
Lubrication without excessive hydrophobicity	Sodium stearyl fumarate	May offer an alternative to magnesium stearate
Tablet strength	Hypromellose and compression excipients	Limits friability during packaging and transport
Patient acceptability	Flavor, sweetener, and color	Important in repeated six-dose treatment

Taste masking is a major commercial differentiator. Pediatric malaria treatment often fails at the administration stage rather than at the level of pharmacology. A dispersible tablet that leaves a bitter residue, floats on water, or requires prolonged stirring can reduce dose completion.

What commercial opportunities exist in Coartem excipient technology?

Lactose-free and low-allergen formulations

Lactose is inexpensive and widely used, but a lactose-free formulation could support procurement specifications, patient segmentation, and differentiated branding. Potential replacements include mannitol, microcrystalline cellulose, spray-dried polyols, and directly compressible starch systems.

A substitute must preserve tablet hardness, dispersion time, dissolution, taste, and humidity stability. Mannitol can improve mouthfeel but may increase tablet cost and alter compression behavior. Microcrystalline cellulose can improve compactability but may produce a more persistent residue in dispersible products.

Improved taste masking for pediatric products

Taste-masking technologies have a direct commercial rationale for artemether/lumefantrine. Candidate platforms include:

• Ion-exchange resins.
• Polymer coating of drug particles.
• Lipid or wax-based taste barriers.
• Spray-dried drug-excipient microparticles.
• Flavored effervescent or rapidly dispersing matrices.
• Multi-particulate granules with controlled release of bitterness.

The primary development risk is that taste-masking coatings can delay lumefantrine dissolution or reduce bioavailability. Any new system must demonstrate equivalent exposure and reliable dissolution under biorelevant conditions.

Low-water or spoon-free administration

Water availability can be limited in rural malaria settings. Commercial opportunities include:

• Orally disintegrating tablets.
• Directly dispersible tablets requiring minimal water.
• Orodispersible granules.
• Unit-dose powder sachets.
• Multiparticulate formulations administered with soft food.
• Liquid-free pediatric dosage forms.

The most attractive designs are likely to combine rapid dispersion with low packaging cost. Sachets can reduce tablet compression requirements but introduce filling, humidity, and dose-uniformity challenges.

Tropical-climate stability

Heat and humidity are significant product-quality risks. Excipients and packaging can be engineered to reduce moisture uptake, tablet softening, sticking, and dissolution drift. Relevant approaches include:

• High-barrier blister packaging.
• Desiccant-containing bottles.
• Moisture-resistant film coatings.
• Low-hygroscopic diluents.
• Optimized granulation and residual-moisture controls.
• Excipient grades with tighter particle-size and water-activity specifications.

In public-health procurement, packaging is part of the formulation economics. A slightly more expensive excipient system can be commercially preferable if it reduces product loss, recalls, or temperature-sensitive distribution requirements.

What formulation patents protect Coartem and its excipient strategy?

Coartem’s original commercial protection was centered primarily on the artemether/lumefantrine combination and product development rather than on a broad, durable exclusivity position for common excipients. Standard excipients such as lactose, starch, croscarmellose sodium, hypromellose, colloidal silica, and magnesium stearate are generally difficult to protect broadly because they are established pharmaceutical materials.

Potentially protectable subject matter includes:

• Specific particle-size distributions.
• Drug-to-excipient ratios.
• Taste-masked artemether/lumefantrine particles.
• Dispersible tablet compositions with defined dispersion times.
• Dissolution profiles for lumefantrine.
• Stabilized solid dispersions.
• Manufacturing processes that improve content uniformity.
• Packaging and moisture-control systems.
• Pediatric dosing methods linked to weight bands.

The practical value of a formulation patent depends on claim scope, freedom to operate, validity, enforceability, and whether a generic can design around the claimed excipient combination.

When does Coartem lose exclusivity and what is the Orange Book status?

Coartem no longer depends on a strong current U.S. small-molecule exclusivity position for commercial protection. The product’s core active-ingredient and formulation opportunities are subject to generic competition, regulatory approval, procurement substitution, and market-specific registration.

The FDA Orange Book identifies approved drug products and relevant patent or exclusivity information. The current Orange Book entry and FDA patent-listing records should be used to confirm any active U.S. patents, pediatric exclusivity, or listed regulatory exclusivity associated with NDA 022268 (U.S. Food and Drug Administration, 2024).

Protection category	Coartem relevance
New chemical entity exclusivity	Expired
Core combination protection	Historical; generic competition exists
Pediatric exclusivity	Historical regulatory benefit, not a durable current barrier
Formulation exclusivity	Potentially relevant only where a specific claim remains enforceable
Biosimilar exclusivity	Not applicable; Coartem is a chemically synthesized small molecule
Orange Book patents	Must be checked against the current FDA listing
Regulatory market access	Varies by country and procurement authority

Which companies are challenging Coartem through generic competition?

Generic competition comes from manufacturers of artemether/lumefantrine tablets and dispersible products, including companies supplying national malaria programs, private pharmacies, and global-health procurement channels. Competition is often shaped more by World Health Organization prequalification, national registration, supply capacity, and tender pricing than by U.S. Paragraph IV litigation.

A Paragraph IV challenge is a U.S. Hatch-Waxman mechanism for contesting listed patents. It is less commercially important for Coartem than for high-value chronic medicines because malaria products are often sold through international tenders and donor-funded channels. Generic applicants can pursue approval after relevant exclusivity expires or use jurisdiction-specific pathways where patent barriers are absent.

What is the litigation and settlement status for Coartem?

No major, current U.S. litigation or settlement structure is central to the commercial outlook of Coartem in the way that patent settlements affect blockbuster chronic therapies. The principal competitive risks are regulatory approval, quality compliance, procurement qualification, manufacturing scale, and reliable supply.

Where a generic applicant faces a live formulation or method-of-use patent, settlement terms could affect launch timing. Those terms would need to be reviewed in the relevant court docket, FDA patent records, and national registration databases. Publicly available product information does not establish a current, market-defining Coartem settlement that controls global generic entry.

What manufacturing and intellectual-property barriers affect generic entry?

The active ingredients are available from multiple pharmaceutical supply chains, but manufacturing quality remains a barrier. Key technical issues include:

1. Lumefantrine’s low aqueous solubility and dissolution sensitivity.
2. Uniform distribution of two active ingredients with different physicochemical properties.
3. Reliable production of dispersible tablets at high volume.
4. Taste masking without reducing bioavailability.
5. Stability under heat and humidity.
6. Compliance with WHO, FDA, and national quality standards.
7. Packaging that survives long distribution routes.
8. Consistent pediatric dose recovery after dispersion.

A generic can avoid a narrow formulation patent by changing diluents, disintegrants, lubricants, flavor systems, or granulation methods. The greater barrier is proving equivalent performance at commercial scale.

How does Coartem compare with generic artemether/lumefantrine products?

Factor	Coartem	Generic artemether/lumefantrine
Brand recognition	High in malaria treatment markets	Varies by country
Pediatric dispersible platform	Established	Differentiation varies
Excipient innovation	Mature reference-product system	Opportunity for taste, stability, and cost improvement
Regulatory reliance	Reference product and established evidence	Bioequivalence and local requirements
Procurement position	Strong historical presence	Often price and supply driven
Patent leverage	Limited compared with early lifecycle	Design-around opportunities
Commercial moat	Clinical familiarity, distribution, quality record	Manufacturing scale, price, local access

The strongest generic strategy is not a simple tablet copy. It is a product that combines equivalent exposure with better taste, lower cost, more robust packaging, and dependable supply.

What revenue exposure and licensing opportunities exist?

Coartem revenue is exposed to generic substitution, public procurement pricing, donor funding, malaria incidence, resistance-management policy, and Novartis portfolio priorities. The most attractive licensing opportunities are likely to involve technology platforms rather than a license to the established Coartem brand.

Potential deal structures include:

• Licensing taste-masked artemether/lumefantrine granules.
• Regional rights for pediatric dispersible products.
• Contract manufacturing for WHO-prequalified supply.
• Excipient-supplier partnerships for tropical-stability systems.
• Technology transfer for low-cost direct compression.
• Co-development of sachets or orally disintegrating products.
• Local manufacturing agreements in malaria-endemic countries.

A formulation license is strongest when it includes validated scale-up data, dissolution methods, stability data, and regulatory support. An excipient composition alone is less defensible unless it produces a measurable performance advantage.

What generic launch scenarios exist for Coartem?

Immediate substitution scenario

A generic launches with a conventional 20 mg/120 mg tablet and competes on price. This is the lowest-differentiation route and is most exposed to tender pressure.

Pediatric differentiation scenario

A manufacturer launches a dispersible product with superior taste, rapid dispersion, and low residue. This can support premium positioning in private markets and improve procurement competitiveness where pediatric adherence is prioritized.

Tropical-stability scenario

A product combines humidity-resistant excipients with high-barrier packaging. This approach targets national programs with long, difficult supply chains.

Platform licensing scenario

An excipient or drug-delivery company licenses a formulation platform to regional manufacturers. The value lies in repeatable manufacturing and regulatory transfer rather than in a single country launch.

How strong is the Coartem patent estate?

Coartem’s current patent strength is weaker than its historical commercial position. The core molecule-combination protection is mature, standard excipients are difficult to monopolize broadly, and biosimilar barriers do not apply. Residual strength may exist in narrow formulation, process, packaging, or method-of-use claims, but those claims require current jurisdiction-by-jurisdiction review.

The durable commercial barriers are operational:

• Regulatory compliance.
• WHO prequalification.
• Pediatric acceptability.
• Dissolution and bioequivalence.
• Procurement qualification.
• Manufacturing capacity.
• Supply continuity.
• Local registration and distribution.

Key Takeaways

• Coartem is a mature artemether/lumefantrine product with limited reliance on current molecule-level exclusivity.
• Its key excipients support compression, rapid disintegration, wetting, taste, and manufacturing flow.
• The strongest commercial opportunities are pediatric taste masking, low-water administration, lactose-free systems, tropical stability, and lower-cost manufacturing.
• Coartem Dispersible is the most important formulation benchmark for innovation.
• Generic entry is driven more by quality, procurement, WHO qualification, and supply reliability than by Paragraph IV litigation.
• Biosimilar risk is not applicable because artemether and lumefantrine are small-molecule active ingredients.
• Formulation patents may protect narrow compositions or processes, but common excipient combinations have limited standalone exclusivity value.
• Licensing value increases when an excipient system delivers validated dissolution, stability, scale-up, and regulatory advantages.

FAQs

Is Coartem lactose-free?

The conventional Coartem and Coartem Dispersible formulations identified in product information contain lactose monohydrate. A lactose-free generic would require a different excipient system and must demonstrate equivalent quality and bioavailability.

Can mannitol replace lactose in artemether/lumefantrine tablets?

Mannitol can replace lactose as a diluent in some designs, but the substitution can alter compression, mouthfeel, dispersion, hygroscopicity, dissolution, and cost. The replacement requires formulation and bioequivalence validation.

What is the best excipient for masking lumefantrine bitterness?

No single excipient is universally optimal. Polymer coatings, ion-exchange resins, lipid barriers, and multi-particulate systems are credible approaches, but the selected technology must preserve lumefantrine dissolution and exposure.

Are artemether/lumefantrine products eligible for biosimilar approval?

No. Biosimilar pathways apply to biological products. Artemether/lumefantrine products are regulated as small-molecule pharmaceutical products and generally use generic drug approval pathways.

Can an excipient supplier patent a Coartem substitute?

An excipient supplier may patent a novel composition, particle architecture, process, or performance-defined formulation. A patent covering only established excipients used in routine proportions would face substantial novelty and obviousness challenges.

References

European Medicines Agency. (2009). Riamet: EPAR product information. https://www.ema.europa.eu/

Novartis Pharmaceuticals Corporation. (2023). Coartem (artemether and lumefantrine) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

World Health Organization. (2023). World malaria report 2023. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023